|

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

RECRUITINGSponsored by Technische Universität Dresden
Actively Recruiting
SponsorTechnische Universität Dresden
Started2010-09
Est. completion2030-09-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03188874

Summary

This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia. Investigator's sites: 51 sites in Germany. Primary objectives: * Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
* Age ≥ 18 years. There is no upper age limit.
* Signed written informed consent

Exclusion Criteria:

* there are no exclusion criteria

Conditions2

Acute Myeloid Leukemia (AML)Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.